Do some EGFR mutation subtypes benefit from immune checkpoint blockade?May 17, 2019Lung CancerOncology
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLCApril 30, 2019Lung Cancer
Five-fraction SRBT schedule well tolerated with high tumor-control rate in central lung cancersApril 9, 2019Lung Cancer
